IAVI Report

Researchers describe the experimental HIV vaccine approach called germline targeting as “shepherding” the immune system. They hope it will lead to greener pastures.

John Nkengasong warns against complacency setting in as vaccines trickle into many African countries.

In conversation with four experts who are applying lessons from the decades-long battle against HIV/AIDS to the ongoing COVID-19 pandemic.

Scientists are applying decades of HIV research experience to the development of SARS-CoV-2 vaccines in the race to end the pandemic.

Numerous monoclonal antibodies are already in development for both treatment and prevention. There are many unanswered questions, but, if they work, antibodies may play a role in ending this...

An interview with Seth Berkley, chief executive officer of Gavi, the Vaccine Alliance

SARS-CoV-2 is the first Disease X. There will certainly be others. Will the world be better prepared for the next one?

Regulatory approval of a vesicular stomatitis virus-based vaccine paves the way for use of this viral vector in other vaccines.

A slew of potential advances in treating and preventing tuberculosis offers new hope in the battle against one of the oldest human afflictions.

Over hundreds of years, researchers have matched contemporary scientific tools to address the infectious disease threats of their times.

Maria Grazia Pau, senior director, compound development team leader for HIV vaccine programs at the Janssen Pharmaceutical Companies of Johnson & Johnson, talks with IAVI Report about the start of...

Drone delivery may help overcome the challenge of getting medicines and vaccines to hard-to-reach populations.

A conversation with Anatoli Kamali and Penny Moore about the rise of HIV vaccine science in Africa

Africa is contributing far more than samples to scientific research. The continent’s scientists are actively engaged in developing and testing novel HIV vaccine candidates.

Marianne Mureithi is part of a team of researchers that just received highly competitive funding to study mucosal immune responses to HIV in Kenya.

We must continue to engage local investigators and develop their capacity to conduct more basic and clinical research on the African continent.

If you are a regular IAVI Report reader, it will come as no surprise that antibodies, particularly those that are both potent and able to neutralize a broad swath of global HIV isolates, are all the...

More HIV-infected people than ever before are receiving life-saving treatment. Despite this progress, HIV incidence rates remain virtually static.

Although challenges remain, the growing field of mRNA-based vaccine development seems to have a bright future, with potential for preventing cancer, flu, and HIV.

Paul Stoffels of Johnson & Johnson talks about the company’s broad HIV portfolio and the role of industry in advancing vaccine research.

The pandemic isn’t over, but that might be what donors are hearing.

After decades of work, scientists are now advancing rationally designed vaccine candidates meant to induce a long sought-after broadly neutralizing antibody response.

By Kristen Jill Kresge The vaccine world lost another of its great leaders recently with the passing of Adel Mahmoud, a physician, scientist, and professor who played a critical role in the...

Coalition awards US$174 million in grants for research targeting Nipah virus, Lassa fever, and MERS.

By Mark Feinberg, MD, PhD We are at a defining moment in the history of HIV vaccine research. It is not an exaggeration to also propose that, thanks to the fruits of decades of HIV vaccine research and...

Linda-Gail Bekker talks about how she came to work on HIV and shares her thoughts on an evolving field.

Several areas of progress in using antibodies for HIV prevention were showcased at the recent Keystone Symposia.

Influenza, like HIV, is a highly variable menace. A particularly bad flu season has researchers seeking ways to make a better vaccine, and in doing so, there may be lessons from, and for, HIV...

Jonathan Quick describes how the right mix of science, funding, leadership, and communication can come together to secure the world against future epidemics.

The battle against HIV/AIDS lost another great soldier recently with the passing of Australian immunologist and clinician David Cooper on March 18. Cooper was a pioneering scientist and champion for HIV...

Remembering Bonnie Mathieson: A champion of young scientists At the Annual Scientific Retreat in 2016 for the Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Design (CHAVI-ID), Bonnie...